Early this month, I strayed away from one of my key investing tenets; only commit capital to a company that has a long history of solid operating performance. Zynex (ZYXI), whose primary line of business is the sale of electro-therapy devices and supplies for use in pain management, has had a hard time finding their identity in the last decade. Their injured past has included several launched and then quickly discontinued lines of business and subsidiaries, flunked acquisitions, regular turnover in the CFO position, liquidity issues, a lengthy loan default, resultant consecutive